The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.02
Bid: 1.82
Ask: 2.19
Change: 0.00 (0.00%)
Spread: 0.37 (20.33%)
Open: 2.02
High: 0.00
Low: 0.00
Prev. Close: 2.02
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

30 Sep 2015 07:05

RNS Number : 6273A
Immupharma PLC
30 September 2015
 

 

FOR IMMEDIATE RELEASE

30 SEPTEMBER 2015

 

 

 

TIM MCCARTHY APPOINTED AS NON-EXECUTIVE CHAIRMAN

 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect.

 

Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera, Harvard Healthcare and Expedeon Holdings. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

 

A Fellow of the Association of Chartered Certified Accountants, Mr McCarthy has an MBA from Cranfield School of Management.

 

 

Commenting on Tim McCarthy's appointment, Dimitri Dimitrou, Chief Executive Officer, said:

 

"We are delighted to have Tim join ImmuPharma as Chairman. This appointment represents a further strong addition to the Board. Tim's commercial and industry background together with capital markets experience will be extremely valuable as ImmuPharma progresses its lead compound, LupuzorTM, through its pivotal Phase III trial, as well as providing guidance on ImmuPharma's long term business strategy."

 

 

Current Directorships

Ark Analytics Solutions Limited

BBN International Limited

Dropped Limited

Expedeon Holdings Limited

Frangipani Dreams Limited

Harvard Healthcare Limited

Incanthera Limited

Spear Therapeutics Limited

Unnamed Limited

Wise Old Owl Limited

 

Directorships in the Last 5 years

Retail Service Team Limited*

 

\* This company entered into a Creditors Voluntary Winding-up on 12th December 2013, 8 months after Mr McCarthy's resignation of directorship. It was dissolved on 4 June 2015.

 

 

 

There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

For further information please contact:

 

ImmuPharma plc

+ 44 (0) 20 7152 4080

Dimitri Dimitriou, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413 496

Panmure, Gordon & Co., NOMAD & Broker

+ 44 (0) 20 7886 2500

Fred Walsh, Duncan Monteith, Corporate Finance

Charles Leigh-Pemberton, Corporate Broking

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPKCDNOBKDNCB
Date   Source Headline
19th May 20107:01 amRNSInitiation Of Phase I/IIA Studies In Cancer
19th May 20107:00 amRNSPreliminary Results
8th Apr 20109:26 amRNSBest Drug Development Company in Europe Award
5th Jan 20103:00 pmRNSAdditional Listing
5th Jan 20107:00 amRNSING take 4% stake in ImmuPharma plc
3rd Dec 20097:00 amRNSR&D Symposium at the CNRS in Paris
19th Nov 20097:00 amRNSPositive Final Lupuzor Trial Results
19th Oct 200910:31 amRNS'Best Technology 2009' Award at the AIM Awards
9th Oct 200910:14 amRNSAppointment of Joint Broker
29th Sep 20097:00 amRNSInterim Results
21st Sep 20099:55 amRNS8th Annual Bio Investor Forum
17th Sep 20097:00 amRNSJMP Healthcare Focus Conference
24th Jul 200912:12 pmRNSResult of AGM
23rd Jul 20094:17 pmRNSDirectors' Dealings
30th Jun 20097:00 amRNSAnnual Report and Accounts
24th Jun 20097:00 amRNSPreliminary Results
17th Jun 20097:00 amRNSPiper Jaffray Europe Conference
23rd Mar 20097:00 amRNSDirectors' Dealings
4th Feb 200912:32 pmRNSShare Options
2nd Feb 20092:33 pmRNSCephalon license exercise
30th Jan 20097:00 amRNSSuccessful trial results
22nd Dec 200812:00 pmRNSfurther instalment of grant
25th Nov 20087:00 amRNSOption Agreement with Cephalon
12th Nov 20087:00 amRNSGrant Award
21st Oct 20089:31 amRNSPatents Granted
17th Oct 20084:22 pmRNSAdditional Listing and Total Voting Rights
25th Sep 20087:00 amRNSInterim Results
5th Aug 20083:44 pmRNSAGM Result
10th Jul 20087:00 amRNSSecond Placing
2nd Jul 20087:30 amRNSToxicology study
2nd Jul 20087:00 amRNSFund Raising
30th Jun 20083:00 pmRNSAnnual Report and Accounts
20th May 20087:00 amRNSPre-clinical Data
13th May 20086:00 amRNSTrademark Approval
8th May 20087:00 amRNSPreliminary Results
26th Feb 20087:00 amRNSPhase IIb Trial of IPP-201101
8th Jan 20087:00 amRNSNovel Drug Candidate
18th Dec 200712:51 pmRNSDirectors' Dealings
6th Dec 20077:01 amRNSInitiation of Phase IIb trial
16th Nov 200712:28 pmRNSAppointment of Nomad
28th Sep 20077:02 amRNSInterim Results
22nd Aug 20077:00 amRNSCompound Discovery
20th Aug 200710:17 amRNSAIM Rule 26
13th Aug 20074:17 pmRNSDirectors' Dealing
6th Aug 20072:40 pmRNSGrant of Options
10th Jul 20077:01 amRNSPivotal phase II/III trial
13th Jun 20072:00 pmRNSAGM and Board Update
1st May 20077:02 amRNSPreliminary Results
27th Apr 20074:02 pmRNSBoard Appointment
15th Feb 20077:01 amRNSAppointment of adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.